Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $0.05, $0.54 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $56.37 million versus the consensus estimate of $12.2 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.